Abcentra

Abcentra is a private, clinical-stage biotech founded in 2018, targeting the multi-billion dollar coronary artery disease market through a novel anti-inflammatory approach. Its lead asset, orticumab, is a first-in-class monoclonal antibody against oxidized LDL (oxLDL) and is currently in a Phase 2b trial (FORTIFY) for cardiovascular disease. The company is led by CEO Chris Farina and has strengthened its scientific credibility with the appointment of renowned cardiology researcher Dr. Peter Libby to its board. Abcentra operates in a competitive but high-opportunity space, aiming to provide a safer, more targeted alternative to existing broad anti-inflammatory therapies for CAD.

Monoclonal antibody platform targeting oxidized low-density lipoprotein (oxLDL) to specifically inhibit plaque inflammation in atherosclerosis.

Abcentra competes in the cardiovascular inflammation space, which was validated by Novartis's canakinumab (IL-1β inhibitor). However, it aims to differentiate through superior specificity by targeting oxLDL directly in the plaque, rather than systemic cytokines. It also faces competition from other novel anti-inflammatory mechanisms and entrenched standard-of-care drugs.